Generics Bulletin’s Top 50 Ranking For 2022
Compiling All The Data From Our List Of The Top Industry Players
Executive Summary
This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
You may also be interested in...
Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
What Aspects Will Give Humira Biosimilars The Edge In 2023?
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Olon Expands On Multiple Fronts
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.